Sanofi snaps up inhaled insulin licence


Pharma major Sanofi has struck a licensing deal with US firm Mannkind to develop and commercialise Mannkind’s recently-approved Afrezza inhaled insulin powder for global distribution.

Sanofi will pay $150 million (£89 million) up front, plus up to $775 million in performance milestones. Mannkind will continue to manufacture the product, but Sanofi will cover regulatory and development activities, including expanding manufacturing capacity.


Related Content

Inhaled insulin approved in US

30 June 2014 Business

news image

European committee recommends approval for generic long-acting insulin

Compulsory licences: necessity or threat?

23 May 2013 Comments

news image

Are compulsory licences for patent-protected drugs a necessary measure, or a threat to innovation?

Most Read

Lawrencium experiment could shake up periodic table

9 April 2015 Research

news image

Measurement of first ionisation energy confirms electronic configuration but opens up an important debate

Super-fast charging aluminium batteries ready to take on lithium

7 April 2015 Research

news image

New battery charges in under a minute and still performs perfectly after being recharged thousands of times

Most Commented

Women twice as likely to be hired for academic posts as men

17 April 2015 News and Analysis

news image

Experiment shows that faculty staff are more likely to pick women for job roles based on hypothetical CVs

DNA 'barcodes' used to track food

30 October 2014 Research

news image

Milk has been successfully tracked as it is turned into cheese and yogurt in an advance that could fight food fraud